A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .

Inclusion Criteria:

• The subjects volunteered to join the study and signed informed consent form (ICF) withgood compliance;
• Age: ≥ 18 years old, ≤75 years old (when signing ICF); Eastern Cooperative OncologyGroup Performance Status (ECOG PS) score: 0-1; The expected survival period is morethan 3 months;
• Subjects: patients diagnosed as CLL/SLL according to the revised diagnostic criteriaof 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines;
• Computed Tomography / Magnetic Resonance Imaging (CT/MRI) of patients with SLL showedmeasurable lesions;
• Female subjects of childbearing age should agree to use contraceptive measures (suchas intrauterine devices, contraceptives or condoms) during the study period and within 6 months after the end of the study; serum pregnancy/urine pregnancy test within 7days before study enrollment;

Exclusion Criteria:

• Complicated diseases and medical history:

1. It has appeared or is currently suffering from other malignant tumors within 3years before the first medication. The following two situations can be includedin the group: other malignant tumors treated by single surgery have achieveddisease-free survival (DFS) for five consecutive years; Cured cervical carcinomain situ, non-melanoma skin cancer and superficial bladder tumor [Ta (non-invasivetumor), Tis (carcinoma in situ) and T1 (tumor infiltrating basement membrane)];
2. Lymphoma/leukemia is known to involve the central nervous system (CNS);
3. Previously received allogeneic hematopoietic stem cell transplantation;
4. Received autologous hematopoietic stem cell transplantation within 3 monthsbefore the first medication;
5. Unresolved toxic reaction ≥ CTCAE grade 1 caused by any previous treatment;
6. Arterial/venous thrombotic events occurred within 6 months before the firstmedication, such as cerebrovascular accidents (including transient ischemicattack, cerebral hemorrhage and cerebral infarction), deep venous thrombosis andpulmonary embolism;
7. Subjects with any serious and/or uncontrollable diseases;

• Tumor-related symptoms and treatment:

1. He has received chemotherapy and radiotherapy within 4 weeks before the firstmedication, immune checkpoint inhibitor and Chimeric Antigen Receptor T (CAR-T)-Cell Immunotherapy within 12 weeks before the first medication, and othersmall molecule anti-tumor treatments (the elution period is calculated from theend of the last treatment) before the first medication are within 5 half-lives;
2. previously received BCL-2 inhibitors;

• Research-related treatment: received the vaccine within 4 weeks before the firstmedication, or planned to be vaccinated during the study;
• Participated in clinical trials of other antineoplastic drugs within 4 weeks beforethe first medication;
• According to the investigators' judgment, there are patients with accompanyingdiseases that seriously endanger the safety of the subjects or affect the completionof the study, or subjects who think that there are other reasons that are not suitablefor inclusion.
• Allergic to allopurinol and benzbromarone.